What are the side effects of PT-141 (Bremelanotide)?
The most commonly reported PT-141 (Bremelanotide) side effects are nausea (most common, severe in first uses), facial flushing, headache. Most are mild and tend to be dose dependent. It is generally avoided with uncontrolled hypertension. Human clinical evidence for PT-141 (Bremelanotide) is limited, so this reflects reported and observed effects, not a complete safety profile.
Reported PT-141 (Bremelanotide) side effects
- Nausea (most common, severe in first uses)
- Facial flushing
- Headache
- Transient blood pressure increase
- Skin / mole darkening with frequent use
Who should avoid it
- Uncontrolled hypertension
- Cardiovascular disease
- Personal history of melanoma
Bloodwork worth tracking
- Blood pressure baseline if using regularly
References
- Bremelanotide for HSDD in premenopausal women — Kingsberg SA et al., Obstet Gynecol, 2019
- Prespecified and Integrated Subgroup Analyses from the RECONNECT Phase 3 Studies of Bremelanotide — Simon JA, Kingsberg SA, Portman D, et al.; Journal of Women's Health; 2022
- Responder Analyses from a Phase 2b Dose-Ranging Study of Bremelanotide — Althof S, Derogatis LR, Greenberg S, et al.; Journal of Sexual Medicine; 2019
Pepdex is an editorial reference, not medical advice. Peptides vary in legal and approval status by country, many are research compounds without full human safety data. Talk to a qualified clinician before starting anything.
More on PT-141 (Bremelanotide)
Last updated 2026-06-06.